We are exploring whether adding PARP inhibitors can improve outcomes for patients receiving Peptide Receptor Radionuclide Therapy for cancer. This study aims to see if the combination leads to better treatment results.
Health conditions and diseases that the clinical trial is designed to study and treat.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a type of cancer that arises from neuroendocrine cells in the digestive system and pancreas. These tumors can be locally advanced or metastatic, leading to symptoms such as abdominal pain, changes in bowel habits, and hormonal imbalances.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.